ImetelChat

Odds are the meeting will be about BAT for MF and MDS. bp

Hi Sargasso, hmm, a poker player... The real tell was when Scarlett said at the beginning: "this may be bigger than all of us". But a poker player would look hard to see if this was a "tell" or a set up for a "sting". They look the same and a good poker player makes them look exactly the same, and S...

Yes

www.impactjournals.com/oncotarget/ Oncotarget, Advance Publications 2017 Telomerase antagonist imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma Xuping Wu1,*, Jing Zhang2,*, Sijun Yang3 , Zhihui Kuang2, Guolei Tan1, Gang Yang1, Qichun Wei4, Zhigang Guo2 Hat tip to Chen...

Minor changes updated on CT site. One site withdrawn (Tampa). Also appears to confirm status of recruiting as opposed to enrolling, which we know they are not doing. But recruiting for a time when they do is good. bp

Thank you. bp

For Jayfish: From Anna. bp

Sargasso, I know Fish mentioned this too which would be a good sign I think. I just can't place the source of this info, can you or Fish provide a link or a source? Thanks, bp

One more point: If we are receiving honest information several "unprecedented" CR's and PR's (not to mention CI's) are out there right now. (Mayo data plus J and J--I am presuming some effect in the J and J population which admittedly is an unknown but the study continues so there must be something ...

I have been asked in a different forum why I made a comment that April may be the time for data release. Its just a guess but consider this. The September surprise was Sept 12th or so I think. At that time enrollment stopped and at least 20 patients had made it to 12 week mark in the high dose group...

I have not seen mention of the Medalist trial in Gerons materials before. Did I miss it? The trial has similar end points as the Geron/Janssen MDS trial. It looks like luspatercept is a super EPO that treats anemia. It does not appear to target the malignant clone so Imetelstat's uniqueness may favo...

Worth checking out on Geron website. Slide handout for investors prevention. Updated. bp

Hi Scotty, yes there were as far as I remember. Ligas, has parsed out the numbers and might provide them for us. bp

"In my opinion, all non-transplant candidates with high or intermediate-2 risk disease should first be offered participation ininvestigational drug therapy before treatment with conventional drugs including JAK inhibitors. This is because the latter agents are unlikely to significantly modify the na...

Now hold on here laddie my reference to leukwarm conclusions referenced the Comfort study, not Imetelstat. I continue to be struck about Dr Ts strong hints that Imetelstat may prevent progression to AML sorry for the confusion bp

Happy New Year greetings to all. The New Year brings us an excellent new article from Dr. T (available on internet): Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management (published in Nov 2016) Imetelstat mentioned in last paragraph. Dr. T reviews Comfort studies. Sam...

The new website is pretty nice. It emphasizes patience. Wonder why that's relevant. Just kidding. So why would they update the website now? Not for J and J who already has had a chance to look up Geron's dress. If the data is bad no one will check out the web site anyway so why waste money there. A ...

Sargasso, the FDA is inscrutable or they would have already approved. If I had to guess I would say they would look very favorably on a 20% CR/PR response. CI on top of that is gravy. bp

Well as we wind down 2016 I do want Fish to know that the work he has put in on this board is not for naught and is greatly appreciated. It has been a good year for discussion and dissection of ideas as will as for support for those of us who at times have floundered, (and may yet wash up on some di...

Fish in reality, he doesn't have to explain a delay or a decision not to proceed (which I don't think is the reality). Thats why all the disclaimers say the information is relevant at the time they say it but subject to future change (and they are under no obligation to tell us if it does). OK how a...